HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments

HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments

Despite a decreasing incidence in Western countries, gastric cancer is among the most common cancer subtypes globally and is associated with one of the highest tumor-related mortality rates. Biomarkers play an increasing role in the treatment against gastric cancer. HER2 was one of the first biomark...

Full description

Bibliographic Details
Main Authors:	Magdalena K. Scheck, Ralf D. Hofheinz, Sylvie Lorenzen
Format:	Article
Language:	English
Published:	MDPI AG 2024-03-01
Series:	Cancers
Subjects:	HER2 gastric cancer trastuzumab T-DXd targeted therapy
Online Access:	https://www.mdpi.com/2072-6694/16/7/1336

Similar Items

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
by: Kimio Yonesaka
Published: (2021-03-01)

HER2-Low Breast Cancer: Current Landscape and Future Prospects
by: Shirman Y, et al.
Published: (2023-08-01)

Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer
by: Huina Zhang, et al.
Published: (2022-12-01)

Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
by: Toshihiko Matsumoto, et al.
Published: (2022-04-01)

Challenges and future of HER2-positive gastric cancer therapy
by: Chenzhe Ma, et al.
Published: (2023-01-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01)

The effect of combinated treatment of a metastatic HER2-positive stomach cancer
by: R A Khvastunov, et al.
Published: (2014-12-01)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
by: Angela Dalia Ricci, et al.
Published: (2021-04-01)

Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
by: Maluki Radford, et al.
Published: (2023-08-01)

Significant effect of posterior line treatment of HER2 positive advanced gastric cancer: A case report
by: Xiaoting Ma, et al.
Published: (2024-04-01)

HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment
by: N S Besova
Published: (2014-09-01)

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
by: Volkmar Müller, et al.
Published: (2018-03-01)

HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target
by: Caroline Fong, et al.
Published: (2022-08-01)

Expression of Her2-Neu in Primary Gastric and Gastroesophageal Adenocarcinoma: An Experience from a Tertiary Center in South India
by: Aditi Damle, et al.

Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report
by: Junzhu Xu, et al.
Published: (2024-01-01)

Long-term survival after multidisciplinary treatments for HER2-positive advanced gastric cancer with multiple liver and lung metastases
by: Satoshi Yoshioka, et al.
Published: (2023-08-01)

Results of the use of trastuzumab combined with different chemotherapy regimens in first-line treatment of HER2-positive disseminated gastric cancer
by: N. S. Besova, et al.
Published: (2019-06-01)

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
by: Tong G, et al.
Published: (2020-04-01)

The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
by: Xinwei Wang, et al.
Published: (2022-07-01)

Identifying HER2 from serum‐derived exosomes in advanced gastric cancer as a promising biomarker for assessing tissue HER2 status and predicting the efficacy of trastuzumab‐based therapy
by: Qian Li, et al.
Published: (2023-02-01)

Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab
by: Sebastian Schade, et al.
Published: (2022-02-01)

MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients
by: Hazel Lote, et al.
Published: (2023-11-01)

Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
by: Kreina Sharela Vega Cano, et al.
Published: (2022-12-01)

Real‐world clinical outcomes of the combination of anti‐PD‐1 antibody, trastuzumab, and chemotherapy for HER2‐positive gastric/gastroesophageal junction cancer
by: Ju Yang, et al.
Published: (2023-04-01)

Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial
by: Tianshu Liu, et al.
Published: (2019-06-01)

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
by: Shanshan Chen, et al.
Published: (2019-10-01)

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
by: Joseph Tintelnot, et al.
Published: (2023-10-01)

Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective
by: Michelle Bradbury, et al.
Published: (2023-12-01)

History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer
by: Shin Ariga
Published: (2023-05-01)

Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
by: Brittney S. Zimmerman, et al.
Published: (2024-02-01)

Efficacy and survival of anti-PD-1 antibody in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy as first-line treatment of HER2-positive metastasis gastric adenocarcinoma: a retrospective study
by: Ting Deng, et al.
Published: (2023-05-01)

Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast Cancer∗
by: Erica L. Mayer, MD, MPH
Published: (2020-06-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.
by: Elda eTagliabue, et al.
Published: (2014-11-01)

Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient
by: Junyi Wu, et al.
Published: (2022-01-01)

Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment
by: Hyun Jung Kwon, et al.
Published: (2023-05-01)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
by: Liu Yang, et al.
Published: (2022-04-01)

Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions
by: Jiazheng Yu, et al.
Published: (2024-05-01)

Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
by: Deng Lan, et al.
Published: (2023-01-01)